This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Big Drugmakers to Bet on After a Great Earnings Season
by Kinjel Shah
Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.
Pfizer-Merck KGaA's Bavencio Fails in 2nd Gastric Cancer Study
by Zacks Equity Research
Pfizer (PFE) and Merck KGaA's Bavencio misses the primary goal in a late-stage study evaluating it as the first-line maintenance therapy for patients with metastatic HER2-negative gastric cancer.
Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed
by Zacks Equity Research
Aerie (AERI) posts a wider-than-expected Q3 loss and lowers guidance.
Mylan's (MYL) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Mylan's (MYL) earnings beat estimates but sales miss the same in the third quarter of 2019. The company updates guidance for 2019.
The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo
Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.
Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales
by Zacks Equity Research
Exelixis (EXEL) reports solid third-quarter 2019 results as Cabometyx maintains momentum.
Bristol-Myers' (BMY) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Bristol-Myers (BMY) beats both earnings and sales estimates in the third quarter, primarily on robust sales of Eliquis and Sprycel.
Glaxo (GSK) Beats Q3 Earnings Estimates, Raises '19 EPS View
by Zacks Equity Research
Glaxo (GSK) beats on earnings and sales in the third quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.
Stock Market News For Oct 30, 2019
by Zacks Equity Research
Benchmarks closed in the negative territory on Tuesday due to Alphabet???s weak earnings report and uncertainties in timely completion of U.S-China Phase one deal.
Healthcare ETFs Win in October: Here's Why
by Sweta Killa
The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.
Strong Q3 Earnings Data Deluge
by Zacks Equity Research
Strong Q3 Earnings Data Deluge
Q3 Earnings Bonanza: GM, MRK, MA & More
by Mark Vickery
GM fought through strike headwinds to beat estimates, Merck's cancer drug performs great, and Pfizer and Mastercard beat, too.
Pfizer (PFE) Rises on Q3 Earnings & Sales Beat, Ups EPS View
by Zacks Equity Research
Pfizer (PFE) beats estimates for third-quarter earnings and sales and raises earnings guidance range for 2019 while tightening revenue outlook.
Pfizer (PFE) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 19.05% and 4.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.
Positive Earnings Results Push Equities to All-Time Highs
by David Borun
A slew of positive results buoys stocks as we head toward the October Fed meeting
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q3 sales, genericization of some older drugs are likely to have hurt the same.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $36.45, marking a -0.03% move from the previous day.
What's in Store for Healthcare ETFs in Q3 Earnings?
by Sweta Killa
With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Pfizer, Qualcomm and Mitsubishi UFJ Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Pfizer, Qualcomm and Mitsubishi UFJ Financial
Factors Setting the Tone for Novartis' (NVS) Q3 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.
Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.
PFE vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
Top Stock Reports for Johnson & Johnson, Boeing & Pfizer
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Boeing (BA) and Pfizer (PFE).